The annual limits provide enough strips to account for normal variations in self-monitoring necessitated by common health changes (e.g., colds, influenza).
On this page: Annual limits | What if more frequent testing is warranted? | Patient resources | Related links
Research shows that most people with type 2 diabetes who are not using insulin do not need to test their blood sugar routinely. There is little evidence that frequent self-monitoring without a medically valid reason improves diabetes care.
Annual test strip limits
Treatment for managing diabetes |
Notes |
Annual limit |
With insulin and without the use of a continuous glucose monitor (CGM) nor a flash glucose monitor (FGM) |
If a patient takes insulin and is not also using a CGM nor an FGM, this limit applies whether or not they are also taking other diabetes medications. |
3,000 |
With insulin and with the use of a CGM/FGM |
If a patient uses a CGM/FGM, they may also occasionally need blood glucose test strips. For example, if they see an error code on their CGM/FGM or if their symptoms don’t match their CGM/FGM readings. |
200 |
Anti-hyperglycemic medications with a higher risk of causing hypoglycemia |
Drugs with a higher risk of hypoglycemia include insulin secretagogues (e.g., sulfonylureas such as glyburide and meglitinides such as repaglinide). |
400 |
Anti-hyperglycemic medications with a lower risk of causing hypoglycemia |
Drugs with a lower risk of hypoglycemia include:
- Alpha-glucosidase inhibitors such as acarbose
- Biguanides such as metformin
- Dipeptidyl peptidase-4 (DPP-4) inhibitors such as linagliptin
- Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists such as tirzepatide
- Incretin mimetics/glucagon-like peptide (GLP-1) agonists such as semaglutide
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors such as empagliflozin
- Thiazolidinediones (TZDs) such as pioglitazone
|
200 |
Through diet/lifestyle |
No notes. |
200 |
Important: If a patient belongs to more than one category, and is not using a CGM/FGM, the higher limit will apply.
If more frequent testing is warranted
In certain circumstances, more testing is warranted, resulting in a need for more strips than a patient's annual limit.
If a patient meets one of the criteria below and is not on insulin or is a patient using a CGM/FGM, PharmaCare covers 100 extra strips per year, with a Special Authority request from a prescriber or health professional at a diabetes education centre or authorized primary care network.
Criteria for additional test strips
Patient has:
- Not met glycemic targets, as determined by a physician, for three months or more
- An acute illness or co-morbidities, which may impact blood glucose control
- Had changes in drug therapy that may impact blood glucose control (e.g., starting or stopping medications that induce hypo- or hyperglycemia, drug-to-drug or drug-disease interactions)
- A job where hypoglycemia presents a significant safety risk (e.g., pilots, air traffic controllers, commercial drivers)
- Gestational diabetes
Additional test strips for a pediatric patient under Nursing Support Services using a CGM/FGM may be requested at the time of initial CGM/FGM request or with a CGM/FGM renewal request (using the CGM/FGM Special Authority request form).
Note: In the rare case that a patient has a medical need for even more frequent testing, or when a patient on insulin needs to test more frequently, an endocrinologist may submit a written request to PharmaCare for additional strips. Requests are considered on a case-by-case basis. The letter should outline the need for the additional strips and the quantity required.
Resources for your patients
- Diabetes Canada
- Blood sugar testing
- Monitoring blood pressure and foot health
- Developing an action plan
Related links
Special Authority criteria
Blood glucose testing